Clinical Trial Update: A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update investigating fluzoparib in combination with apatinib as second-line therapy for extensive-stage small cell lung cancer (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• Fluzoparib (fluzoparib)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Small Cell Lung Cancer Extensive Stage | Phase 1, Phase 2 | Status: UNKNOWN